ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 144

Small Molecule Inhibitor of Bcl-6 Reduces the Tfh Population in Peripheral Blood, Splenic Germinal Center and Ankle Joints in a Collagen-Induced Arthritis Mouse Model of RA

Nitasha Bhatia1, Sedrick Bradley2, Cara McLeod1, Gbemi Olayemi1, Robert Quinet1, William E. Davis3, Jerald Zakem4 and Xin Zhang1, 1Ochsner Medical Center, New Orleans, LA, 2Ochsner Clinic Foundation, New Orleans, LA, 3University of Queensland School of Medicine, Brisbane, Australia, 4Ochsner Medical Center, New Orleans, LA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Animal models, mouse model and rheumatoid arthritis, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) is a common autoimmune disease characterized by chronic joint inflammation, synovial hyperplasia and progressive destruction of cartilage and bone. T follicular helper (Tfh) cells, a CD4+ T cell subset, predominantly located in lymphoid follicles, regulate B cell survival and antibody production in germinal centers. Our previous studies have showed that circulating Tfh cells were significantly increased in active RA patients, correlated with their anti-CCP antibody titer and disease activity. Here, we further investigated the role of Tfh cells in RA pathogenesis in mice with collagen-induced arthritis (CIA) and also examined the therapeutic effect of a small molecule inhibitor (SMI-Tfh) which selectively blocks the Tfh cell signature transcription factor Bcl-6.

Methods:

CIA model was induced by administrating chicken type II collagen in twenty-four DBA/1 mice. The joints were observed for score of swelling of paws and ankles. Disease progression was monitored daily and recorded by arthritis severity scores weekly. Following the onset of clinical arthritis, mice were treated with SMI-Tfh. Blood, spleen, and affected paws were collected at the end of the study. Pathological changes were examined by staining of tissue sections with hematoxylin and eosin. Immunofluorescent histochemistry (IHC) staining and flow cytometry analysis were performed to identify Tfh cells (CD4+CXCR5+ICOS+) in spleen, paw, and blood. IHC results were analyzed by Image J and flow cytometry results were analyzed by FlowJo software. Statistical analysis was carried out using GraphPad Prism software and the significance was evaluated by t test.

Results: Our results showed paw-swelling onset between days 21-28 and with peak on day 42 after initial immunization in DBA/1 mice. Compared with the ankles of control mice, the joints of CIA mice had increased inflammatory cells in the synovial tissues and destruction of articular cartilage. Tfh cells (CD4+CXCR5+ICOS+) were observed in the blood and the germinal centers of the spleen of CIA mice. Mice treated with SMI-Tfh had significantly reduced paw swelling. SMI-Tfh was nontoxic at the tested dose (50mg/kg). SMI-Tfh treatment also reduced inflammatory cell and Tfh cell infiltration in inflamed joints, and significantly inhibited the numbers of Tfh cells in the blood and in the germinal centers of spleen (p<0.01) in CIA mouse.

Conclusion:

Tfh cells originating from splenic lymphoid follicles may contribute to the circulating Tfh cells in the peripheral blood in RA and play an important role in the development of active RA. The small molecule inhibitor SMI-Tfh selectively inhibits Tfh cells in the spleen and in the inflamed joints. It appears to decrease severity in inflammatory arthritis, and may be useful as a new and additional therapeutic modality for RA.


Disclosure: N. Bhatia, None; S. Bradley, None; C. McLeod, None; G. Olayemi, None; R. Quinet, None; W. E. Davis, None; J. Zakem, None; X. Zhang, None.

To cite this abstract in AMA style:

Bhatia N, Bradley S, McLeod C, Olayemi G, Quinet R, Davis WE, Zakem J, Zhang X. Small Molecule Inhibitor of Bcl-6 Reduces the Tfh Population in Peripheral Blood, Splenic Germinal Center and Ankle Joints in a Collagen-Induced Arthritis Mouse Model of RA [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/small-molecule-inhibitor-of-bcl-6-reduces-the-tfh-population-in-peripheral-blood-splenic-germinal-center-and-ankle-joints-in-a-collagen-induced-arthritis-mouse-model-of-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/small-molecule-inhibitor-of-bcl-6-reduces-the-tfh-population-in-peripheral-blood-splenic-germinal-center-and-ankle-joints-in-a-collagen-induced-arthritis-mouse-model-of-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology